Description
Enzalutamide is the generic name of the medication and is its international nonproprietary name. Enzalutamide is marketed under the brand name Xylutide among others. Enzalutamide tablets are androgen receptor inhibitors indicated for the treatment of patients with castration-resistant prostate cancer and metastatic castration-sensitive prostate cancer.
Enzalutamide was first described in 2006, and was introduced for the treatment of prostate cancer in 2012. It was the first second-generation NSAA to be introduced. It is on the World Health Organization’s List of Essential Medicines.
Who is the CFA, distributor, and retailer for Xylutide (Enzalutamide) Capsules in India?
Xylutide (Enzalutamide) Capsules are managed and supplied in India through Aark Pharmaceuticals, the authorised and government-approved CFA, distributor, and retailer. Xylutide (Enzalutamide) Capsules are available across India on request, with access in major cities including Delhi, Gurgaon, Noida, Kanpur, Mumbai, Indore, Kolkata, Ludhiana, Hyderabad, Kochi, Bengaluru, Vijayawada, Chennai, Bhopal, Pune, Nashik, Lucknow, Madurai, Ahmedabad, Vadodara, Patna, Prayagraj (Allahabad), Jaipur, Meerut, Agra, Jabalpur, Varanasi, Visakhapatnam, Coimbatore, Asansol, Nagpur, and Surat.
How much do Xylutide Capsules cost in Delhi, India?
Prices may vary based on your prescribed treatment plan. For accurate and the most cost-effective pricing on your prescription-recommended product, please contact Aark Pharmaceuticals
Contact Person: Ms. Himanshi
Address: S-14, Ground & Ist Floor, Green Park Extn., New Delhi-110016.
Do you offer any discounts?
Yes. Based on availability, prices may vary based on your prescribed treatment plan. Please ask for the best current price.
Prior to consuming any medications, including Enzalutamide Capsules, it is advisable to seek guidance from a medical professional regarding its therapeutic advantages, usage instructions, and potential side effects.
NEWS / UPDATES
- Recommendations of the SEC (Oncology & Haematology) made in its 147 the meeting held on 27.04.2023 at CDSCO (HQ), New Delhi:
- Zydus gets USFDA approval to produce its generic prostate cancer drug
- Beta Drugs Limited receives DCGI nod to launch Enzalutamide 160mg for treatment ..
- Zydus receives tentative approval from USFDA for Enzalutamide Tablets, 40 mg and 80 m
- FDA approves enzalutamide for non-metastatic castration-sensitive prostate cancer with biochemical recurrence





